Aperture Investors’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Aperture Investors’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-6,426	Closed	-$322K	–	95
2022 Q3	$322K	Sell	6,426 -498	-7%	-$34.6K	0.05%	82
2022 Q2	$590K	Buy	6,924 +416	+6%	+$35.6K	0.1%	69
2022 Q1	$982K	Hold	6,508	–	–	0.13%	73
2021 Q4	$1.95M	Sell	6,508 -1,225	-16%	-$470K	0.25%	59
2021 Q3	$3.02M	Sell	7,733 -2,904	-27%	-$1.24M	0.41%	53
2021 Q2	$4.49M	Sell	10,637 -5,016	-32%	-$2.17M	0.51%	53
2021 Q1	$7.47M	Buy	+15,653	New	+$7.97M	1.15%	27

Other funds holding FNCH

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

TRB Advisors New York $146M AUM 3.71% 1-Year Est. Return

SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Aperture Investors's FNCH Position: Q4 2022 in Review

Aperture Investors sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q4 2022, closing a stake of 6,426 shares — an estimated $322K sold.

Aperture Investors first reported a position in FNCH in Q1 2021 and held it in 7 quarters. The position peaked at $7.47M in Q1 2021. 40 funds tracked by Wall St. Rank hold FNCH as of Q4 2022.

Aperture Investors reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Aperture Investors sold 6,426 Finch Therapeutics Group, Inc. Common Stock shares in Q4 2022, an estimated $322K.
Aperture Investors first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Aperture Investors's Finch Therapeutics Group, Inc. Common Stock position peaked at $7.47M in Q1 2021.
40 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q4 2022.

Based on Aperture Investors's 13F filing for Q4 2022, filed 14 Feb 2023.